Hematology Billing Services for Practices That Read Blood to Its Origin

Iron-deficiency anemia is billed with iron sucrose J1756 or ferric carboxymaltose J1439 administered by non-chemo therapeutic infusion under 96365 and additional hours 96366. B12 deficiency is billed as a subcutaneous or intramuscular injection under 96372. Epoetin alfa J0885 and darbepoetin J0881 for non-ESRD anemia of chronic disease are infused under 96365, with the cancer-anemia coverage rules and hemoglobin thresholds documented. We document the start and stop times, the units, and the NDC on every drug line.

38222 is the trephine needle biopsy that removes a core of bone and marrow, and 38221 is the aspiration that withdraws marrow fluid. When both a biopsy and an aspiration are performed the same session, both may be reported only where the documentation supports distinct services and current NCCI edits permit it. We select the code that matches the procedure performed, screen the combination against current NCCI, and never substitute aspiration for biopsy or the reverse.

Therapeutic phlebotomy for polycythemia vera and other indicated conditions is billed under 99195, distinct from routine venipuncture 36415. The diagnosis D45 for polycythemia vera, or the specific iron-overload code such as E83.110 for hereditary hemochromatosis, supports the medical necessity. The volume removed, the patient tolerance, and the post-procedure hematocrit go in the documentation. We confirm the diagnosis, the indication, and the session count before the claim is submitted.

Chemotherapy administration for leukemia, lymphoma, and myeloma is billed under 96413 for the first hour of IV infusion and 96415 for each additional hour beyond the first. Subcutaneous or intramuscular antineoplastic injection is billed under 96411, not the non-chemo injection code. The start and stop times are documented to the minute, the additional hours are reported in full, and the antineoplastic drug is billed with its J-code and NDC. ESA and iron are never billed on 96413, because they are non-chemo drugs and belong on the 96365 track.

96413 covers the first hour of chemotherapy IV infusion, the initial or single substance. 96415 covers each additional hour beyond the first, reported as one unit per additional hour. A chemotherapy infusion that runs two hours bills one 96413 and one 96415, and a three hour infusion bills one 96413 and two 96415 units. The additional-hour code is the one most often missed, because the infusion runs longer than the first hour but only the first-hour code is submitted. We document the total time and report every additional hour.

A blood or blood product transfusion is billed under 36430, with the medical necessity documented, most often symptomatic anemia, acute bleeding, chemotherapy-induced cytopenia, or a coagulopathy. The product transfused, the number of units, and the patient response go in the record, and pre-transfusion typing and crossmatch under 86900 to 86999 are billed where performed. A transfusion reaction is reported with the T80 ICD-10 series. We confirm the indication, the product, the units, and the testing before the claim is submitted.

For Part B drugs supplied in single-use vials, including infused ESA and factor, the JW modifier reports discarded drug that was not administered to any patient, with the discarded units, and the JZ modifier attests that no drug was discarded from the single-use vial. One of the two is required on the claim, and the J-code units and the NDC must reconcile to the administered dose. We append the correct modifier on every single-use vial line and reconcile the units and NDC before submission.

96365 is the first-hour non-chemo therapeutic IV infusion, used for hydration, ESA, iron sucrose, iron dextran, and other non-antineoplastic drugs. 96413 is the first-hour chemotherapy IV infusion, used only for antineoplastic drugs. The distinction is the drug class, not the infusion itself. An ESA infused for anemia of chronic disease bills on 96365, and a chemotherapy drug infused for leukemia bills on 96413. We flag the drug class on every encounter so the infusion lands on the right track, and we never bill a non-chemo drug on a chemo code or the reverse.

The JW modifier reports discarded drug from a single-use vial and is paid at the same rate as the administered dose for the wasted amount, so a vial where only part was infused generates payment for both the administered units and the discarded units. The JZ modifier attests that no drug was discarded and is required on every single-use vial Part B claim where no waste occurred, but carries no additional payment. Reporting JZ incorrectly when waste actually occurred is a recoupment risk. We reconcile the vial size, the administered units, and the discarded units on every line, and append JW or JZ accurately so the drug line pays what the documentation supports.

CAR-T cell therapy billing combines the cellular product code such as Q2041 for axicabtagene ciloleucel, Q2042 for tisagenlecleucel, Q2053 for lisocabtagene maraleucel, or Q2054 for ciltacabtagene autoleucel, the cell collection and processing codes, the administration code 96413 for the IV infusion, and the appropriate inpatient or outpatient encounter codes. Each component is billed on its own claim line with the correct units and the modifier rules per the specific product. The diagnosis is the documented hematologic malignancy subtype, typically a C81 to C86, C90, or C91 code. We verify the specific product code, the administration setting, and the payer CAR-T policy before submission, since requirements vary significantly by payer and product.

Flow cytometry immunophenotyping is billed with 88184 for the first marker and 88185 for each additional marker beyond the first, reported in units based on the total number of markers. The interpretation is billed under 88187 to 88189, selected by complexity, the number of markers reviewed. The diagnosis is the documented hematologic malignancy or unexplained cytopenia. We confirm the marker count, the interpretation level, and the documentation for medical necessity before submission, since flow claims are frequent audit targets.

Sickle cell disease transfusion claims are billed with 36430 for the transfusion, 86920 to 86922 for the crossmatch where performed, and 86900 to 86901 for the typing. The diagnosis is the specific D57 subtype, with crisis status documented where applicable. Exchange transfusion, where performed, is reported with 36455. Chronic transfusion programs for stroke prevention are billed per session with the documentation of the chronic indication on file. We confirm the D57 subtype, the transfusion indication, and the chronic versus acute setting before the claim is submitted.

Hemophilia A and B factor replacement is billed with the factor J-code, the units, and the NDC, with the diagnosis code D66 for hemophilia A or D67 for hemophilia B supporting the claim. For prophylaxis factor replacement, the home-treatment regimen, the factor dosing, and the indication are documented in the record so the prophylaxis claim is supported. We reconcile the factor units to the administered dose, append JW or JZ for single-use vial waste, and document the home-treatment regimen before the claim is submitted.

Anticoagulation monitoring is billed with the prothrombin time 85610 or substitution technique 85611 and INR where performed, the partial thromboplastin time 85730 for heparin and factor monitoring, and the appropriate E/M encounter code that documents the anticoagulation management. Patient self-testing is reported under G0248 for the initial demonstration, G0249 for each subsequent review of home INR testing, and G0250 for the physician review and interpretation where the payer covers it. Anticoagulation management was previously billed under 99363 and 99364, which were deleted from CPT. We confirm the assay performed, the documented encounter, and the diagnosis code before submission.

Von Willebrand disease is billed with the diagnosis code D68.0 supporting the claim, the VWF replacement factor billed with its J-code and units, and desmopressin billed where used for the documented subtype. The subtype, the factor dosing, and the treatment setting, prophylaxis or bleeding episode, are documented in the record. We reconcile the factor units and NDC, append JW or JZ for single-use vial waste, and confirm the subtype documentation before the claim is submitted.